GLPG-3121
/ Galapagos, Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 04, 2022
First key steps in pipeline rebuild and strong commercial progress in H1 2022
(GlobeNewswire)
- "Galapagos NV...today announced its first half-year 2022 financial results...Pipeline update:...Discontinued development of 4 early-stage programs as part of ongoing scientific and strategic exercise: GLPG3121, a local release formulation JAK1/TYK2 inhibitor with potential in inflammatory diseases; GLPG0555, a JAK1 inhibitor evaluated in osteoarthritis; GLPG4586, a compound with undisclosed mode of action directed toward fibrosis; and GLPG4716, a chitinase inhibitor directed toward idiopathic pulmonary fibrosis"
Discontinued • Idiopathic Pulmonary Fibrosis • Inflammatory Bowel Disease • Osteoarthritis
December 03, 2021
A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects
(clinicaltrials.gov)
- P1; N=50; Completed; Sponsor: Galapagos NV; Recruiting ➔ Completed
Clinical • Trial completion
May 04, 2021
A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects
(clinicaltrials.gov)
- P1; N=56; Recruiting; Sponsor: Galapagos NV; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
April 23, 2021
A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects
(clinicaltrials.gov)
- P1; N=56; Not yet recruiting; Sponsor: Galapagos NV
Clinical • New P1 trial
1 to 4
Of
4
Go to page
1